Pharma Marketing Network

Dear Reader, Welcome to the January 2005 archive of Pharma Marketing News. Vol....

CBI's 3rd Annual Product Launches Conference, December 8-9, 2004, provides you with the opportunity to hear case studies from industry leaders on challenges they've faced, solutions they've developed and successes they've had for creating pre-launch strategies to achieve rapid sales uptake. This conference arms you with the toolbox needed to plan and execute a winning launch. Leverage the creativity, intuition and strategy employed by some of the industry’s most notable launches!

Featured Conference Six Sigma for Sales & Marketing in the Pharmaceutical Industry Simplifying and Modifying This Cutting-Edge...

This conference provides insights into the financial implications of patient noncompliance and the ROI of compliance programs.

Attend CBI’s 4th Annual Forum on Generic Drugs to gain a comprehensive look at the important issues impacting today’s Generics Industry and hear insights from industry leaders, regulatory experts and Congressional representatives.

Featured Conference Publication Planning Excellence November 17-18, 2004 • Philadelphia, PA Visit the conference...

Featured Conference Thought Leaders and Key Opinion Leaders (KOLs) November 15-16, 2004 • Philadelphia,...

As an educational and an awareness tool to healthcare professionals around the globe; journal publications are one of the most influential materials available for a brand. This responsibility drives Publication Planning within an organization. It is an essential element to any company within the Pharmaceutical industry.

The Summit will feature 4 pre-conference workshops that provide interactive education and intense focus on key challenges and opportunities for the industry. The main conference features Keynote Addresses, led by the industry’s top strategists and decision-makers.

A few days after Merck pulled Vioxx from the market it was revealed that the drug manufacturer may have known about Vioxx's cardiovascular side effect problems for years and tried very hard to conceal the evidence and block any action by the FDA. While this was going on an estimated 27,000 people suffered heart attacks and who knows how many strokes possibly due to Vioxx! hard to conceal the evidence and block any action by the FDA. While this was going on an estimated 27,000 people suffered heart attacks and who knows how many strokes possibly due to Vioxx! If this obstructionism by Merck is true, then someone should pay.